Icon acquires Mapi Group, ups financial guidances

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Kritchanut)
(Image: iStock/Kritchanut)
Icon plc is expanding its commercialization offerings through its has acquisition of Mapi Group, a global research company.

The Mapi Group was founded in 1974 and provides real-world evidence, strategic regulatory services, pharmacovigilance, market access, and language services to support commercialization.

Through the acquisition, Icon will also have access to Mapi Research Trust, a non-profit that provides outcomes research globally.

Per the company’s website, the Trust features more than 4,000 clinical outcomes assessments (COA), more than 40,000 COA translations, and a research library with more than 29,000 COAs.

Dr. Steve Cutler, Icon CEO commented in the press release: “Our customers will also benefit from ICON’s access to the industry’s broadest set of COA tools and instruments as well as new and enhanced real world data set​s.”

Following the acquisition, Icon has increased its earnings and revenue guidances.

According to the company’s earnings results, also published today, the earnings guidance has been increased from a range of $5.06 - $5.26bn to $5.18 - $5.38bn. Revenue guidance increased from a range of $1.70 - $1.75bn to $1.74 - $1.77bn.

Icon reported gross business wins of $649m in the second quarter and cancelations of $86m, which resulted in net business wins of $563 million and a net book to bill of 1.31.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars